AstraZeneca PLC
corporate_fare Company Profile
AstraZeneca PLC (NYSE:AZN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 66 items for AZN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for AZN spans 6-K.
Recent high-impact activity:
- FDA Approves IMFINZI-Based Perioperative Regimen for Cisplatin-Ineligible Bladder Cancer
- AstraZeneca Q3 Revenue Up 7% at CER, Core EPS Up 19%; FY26 Guidance Reconfirmed and $2.0bn Restructuring Launched
- Q3 EPS Beats at $2.79 as Oncology Sales Jump 17%; New $1.5B Cost-Savings Plan
- Enhertu Wins EU Approval in Early Breast Cancer, Triggering $75M Milestone
- Sone-Ve Cuts Death Risk 42% in Late-Line Gastric Cancer, PFS Endpoint Missed
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 3,032,797 shares in AZN as of the October 30, 2026 settlement, a 7.6% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 13, 2026, 63.0% of AZN volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
AZN files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.